BMS225975

Known as: BMS-225975 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2009
012320042009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
Highly Cited
2008
Highly Cited
2008
Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2008
2008
Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell (HSC) disorder, cannot be eradicated by conventional chemotherapy or… (More)
  • table 1
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, cannot be eradicated by conventional chemotherapy or the… (More)
  • table I
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, cannot be eradicated by conventional chemotherapy or the… (More)
  • table I
Is this relevant?
2005
2005
Farnesyltransferase inhibitors (FTI) have been developed as anticancer drugs and are currently being evaluated in clinical trials… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2004
2004
BMS-214662 and BMS-225975 are tetrahydrobenzodiazepine-based farnesyltransferase inhibitors (FTIs) that have nearly identical… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?